Nyu Langone Health’s Perlmutter Cancer Center announces the arrival of recognized leaders of Anirban Maitra, MD and Manuel Hidalgo, MD, as co-director of a new gastrointestinal cancer center (GI). This marks a milestone in its mission to develop a global innovative GI cancer program with a closely comprehensive research and clinical platform that focuses on translating research into new treatments for patients with GI cancer.
Dr. Maitra is a world-renowned physician-scientist whose project has widely influenced the field of pancreatic cancer research from timely detection and development of the biodegradation to the microenval of the tumor and early cancer monitoring strategies. It is also a leading gastrointestinal and pancreatic physician, and in Nyu Langone, it will work with the Department of Pathology for the development of programs in spatial biology, molecular diagnostics and tissue -based analysis. At Perlmutter Cancer Center, Dr. Maitra will serve both as co-director of the GI Cancer Center and as a partner of translation research, which will lead efforts to lead the discovery from the Lab to the clinic in multiple disease areas.
“We are well in the Perlmutter Cancer Center to create a truly global GI cancer center,” said Dr. Maitra. “The integrated nature of this institution gives us so many opportunities to turn what we do on the workshop bench into tangible treatments, developing both our understanding of these cancers and our ability to improve the results for our patients.”
Dr. Hidalgo is a very respected translation researcher and clinical oncologist, having done internationally recognized work on the development of anti -cancer drugs. It has led to the early clinical development of more than 50 new factors that have changed the care model for patients with advanced cancers. Having pioneering the use of a patient, which use a patient’s volume sample to develop the best course of treatment, Dr. laboratory discoveries. Hidalgo Bridges with clinical application. At the Perlmutter Cancer Center, it will focus on building powerful infrastructure for therapeutic development, tests launched by researchers and biomarkers -based studies.
“I have the honor of joining the Perlmutter Cancer Center and helping to develop this ambitious GI cancer center alongside Dr. Maitra,” Dr. Hidalgo said. “The vision behind this initiative is to facilitate cooperation between the existing Nyu Langone Health expertise to address the needs of our patients’ community.”
Dr. Maitra and Dr. Hidalgo have worked together in the past to develop a successful pancreas cancer center earlier in their career. We are extremely excited that their reunification in Nyu Langone will see them build a GI cancer center that works with the multi -scientific groups of incredible surgical oncologists, oncologists oncologists, medical oncologists, gastroenterologists and researchers to abstain.
John P. Leonard, MD, Head of Division of Hematology and Medical Oncology at NYU Grossman School and Director of the Cancer Center for Cancer Cancer at Perlmutter Cancer Center
